Linda Nussbaum is the founder and Managing Director of Nussbaum Law Group, P.C. (“NLG”), and is nationally recognized for her representation of class and individual plaintiffs in antitrust, RICO, commodities, data breach, and pharmaceutical litigation. She has served in leadership roles in numerous complex class actions resulting in substantial recoveries, often in the hundreds of millions of dollars, and has extensive experience representing both class plaintiffs and large corporate clients in high-stakes direct actions.
Linda is currently serving as a court appointed class lead counsel in:
- In re Payment Card Interchange Fee and Merchant Discount
Antitrust Litigation, 05-md-01720 (E.D.N.Y.) (NLG appointed Co-Lead Counsel) - In re Fragrance Direct Purchaser Antitrust Litigation, 23-cv-02175 (D.N.J.) (NLG appointed Co-Lead Counsel)
- In re Outpatient Medical Center Employee Antitrust Litigation, 21-cv-00305 (N.D. Ill.) (NLG appointed Co-Lead Counsel)In re Generic Pharmaceuticals Pricing Antitrust Litigation, 16-md-2724 (E.D. Pa.) (NLG appointed to Direct Purchaser Plaintiff Steering Committee)
- In re Actos Direct Purchaser Antitrust Litigation, 15-cv-03278 (S.D.N.Y.) (NLG appointed Co-Lead Counsel)
- In re Copaxone Antitrust Litigation, 22-cv-1232 (D.N.J) (NLG appointed to Direct Purchaser Plaintiff Executive Committee)
- Safe Harbor International LLC v. Booz Allen Hamilton Inc., et al., 25-cv-00139 (D. Md.) (NLG appointed Co-Lead Counsel)
- In re Perry Johnson & Associates Medical Transcription Data Security Breach Litigation, 24-md-03096 (E.D.N.Y.) (NLG appointed Lead Counsel Northwell Plaintiff Group)
- In re American Medical Collection Agency, Inc., 19-md-2904 (D.N.J.) (NLG appointed Co-Lead Counsel for the LabCorp Track)
In addition to her current leadership appointments, Linda has held leadership positions in numerous significant class actions that have been successfully resolved, including:
- KPH Healthcare Servs., Inc. v. Mylan N.V., et al., 20-cv-02065 (D. Kan.) (“EpiPen”) (Co-Lead Counsel; settled for over $123 million)
- In re Morgan Stanley Data Security Litigation, 20-cv-5914 (S.D.N.Y.) (Co-Lead Counsel; settled for $60 million)
- In re The Bank of Nova Scotia Spoofing Litigation, 20-cv-11059 (D. N.J.) (NLG appointed Co-Lead Counsel; settled for $6.6 million)
- In re Wawa Inc. Data Security Litigation, 19-cv-6019 (E.D. Pa.) (NLG appointed Co-Lead Counsel; settled for $9 million)
- In re London Silver Fixing, Ltd. Antitrust Litigation, 14-md-2573 (S.D.N.Y.) (L. Nussbaum appointed Co-Lead Counsel; settled for $38 million)
- In re Foreign Exchange Antitrust Litigation, 13-cv-7789 (S.D.N.Y.) (NLG appointed Allocation Counsel; settled for over $2 billion)
- Meijer, Inc. v. Warner Chilcott Public Limited Company, 12-cv-03824 (E.D. Pa.) (Co-Lead Counsel; settled for $15 million)
- In re Puerto Rican Cabotage Antitrust Litigation, 08-md-01960 (D.P.R.) (L. Nussbaum appointed Co-Lead Counsel; settled for $52 million)
- Meijer, Inc. v. Braintree Laboratories, Inc., 07-cv-00142 (D. Del.) (Co-Lead Counsel; settled for $17.5 million)
- Meijer, Inc. v. Abbott Laboratories, 07-cv-05985 (N.D. Cal.) (Co-Lead Counsel; settled for $52 million)
- In re Metoprolol Succinate Direct Purchaser Antitrust Litigation, 06-cv-00052 (D .Del.) (Co-Lead Counsel; settled for $20 million)
- In re DDAVP Direct Purchaser Antitrust Litigation, 05-cv-02237 (S.D.N.Y.) (Co-Lead Counsel; settled for over $30 million)
- Meijer, Inc. v. Warner Chilcott Holdings Co. III, Ltd., 05-cv-02195 (D.D.C.) (Co-Lead Counsel; settled for $22 million)
- In re Foundry Resins Antitrust Litigation, 04-md-01638 (S.D. Ohio) (L. Nussbaum appointed Co-Lead Counsel; settled for $14.1 million)
- In re Children’s Ibuprofen Oral Suspension Antitrust Litig., 04-mc-00535 (D.D.C.) (Lead Counsel; settled for $9.7 million)
- In re Rubber Chemicals Antitrust Litigation, 04-md-01648 (N.D. Cal.) (L. Nussbaum appointed Co-Lead Counsel; settled for $320 million)
- In re Plastics Additives Antitrust Litigation, MDL No. 1684, 03-cv-02038 (E.D. Pa.) (L. Nussbaum appointed Co-Lead Counsel; settled for $46.8 million)
- In re Nifedipine Antitrust Litigation, 03-ms-00223 (D.D.C.) (Co-Lead Counsel; settled for $35 million)
- In re Remeron Antitrust Litigation, 03-cv-0085 (D.N.J.) (Co-Lead Counsel; settled for $75 million)
- Oncology & Radiation Associates, P.A. v. Bristol-Myers Squibb Company & American Bioscience, 01-cv-02313 (D.D.C.) (Lead Counsel; settled for $65.8 million)
- In re Relafen Antitrust Litigation, 01-cv-12239 (D. Mass.) (Co-Lead Counsel; settled for $175 million)
- In re Microcrystalline Cellulose Antitrust Litigation, MDL No. 1402, 01-cv-00111 (E.D. Pa.) (L. Nussbaum appointed Co-lead Counsel; settled for $50 million)
- In re Sorbates Direct Purchaser Antitrust Litigation, 98-cv-04886 (N.D. Cal.) (L. Nussbaum appointed Co-Lead Counsel; settled for $96 million)
- In re Lorazepam & Clorazepate Antitrust Litigation, 99-ms-00276 (D.D.C.) (Co-Lead Counsel; settled for $37 million)
Linda also regularly represents large corporate clients pursuing direct actions and has represented individual plaintiffs in In re Packaged Seafood Products Antitrust Litigation, 15-md-2670 (S.D. Cal.) and in In re American Express Anti-Steering Rules Antitrust Litigation, 11-md-02221 (E.D.N.Y.) during the initial phase of the In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, 05-md-01720 (E.D.N.Y.) where she currently serves as Co-Lead Counsel.
Linda’s successful prosecution of complex class litigation has been recognized and commended by judges in matters in which she has served as lead counsel. Following a five-week jury trial in In re Neurontin Marketing and Sales Practices Litigation, 04-cv-10981 (D. Mass.), where Linda served as Co-Lead Trial Counsel, Judge Patti Saris commented that:
[This was] a fabulous trial[.] [I]t’s the kind of thing that you become a judge to sit on.
Judge Paul A. Engelmeyer, at the final approval hearing in In re Zinc Antitrust Litigation,14-cv3728 (S.D.N.Y.), complemented Linda and her Co-Lead Counsel stating:
I have been truly impressed by counsel’s work in the case. I wish the caliber of lawyering in this case was the model for all cases before me.
Recently, in approving a settlement and fee in KPH Healthcare Servs., Inc. v. Mylan N.V., et al., No. 2:20-cv-02065 (D. Kan.) (“EpiPen”) where Linda represented a proposed class of direct purchasers of EpiPen alleging they were overcharged as a result of defendants’ scheme to delay the entry of generic EpiPen, Judge Daniel Crabtree commended Linda and her Co-Lead Counsel, stating:
The court has observed the skill and zeal Class Counsel has applied to prosecute this case, and it finds that they are experienced, have good reputations, and have performed exceptional legal work on behalf of their clients and the Class.
Linda was selected “Litigator of the Week” by the AmLaw Litigation Daily for her lead trial role in Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals v. Pfizer, 11-cv-07178 (D.N.J.) where, after a five-week trial, a jury returned a RICO verdict for her clients, and was also a finalist for Public Justice Foundation’s 2011 Trial Lawyer of the Year award.
In addition to her courtroom work, Linda is a frequent speaker on antitrust and class action law, including at the American Antitrust Institute Private Enforcement Conference and American Bar Association Section of Antitrust Law Spring Meetings. She has been a member of the American Law Institute for more than 15 years, serves as a long-time advisory board member of the American Antitrust Institute, and sits on the Board of Savvy Ladies, a nonprofit organization providing legal and financial resources to women.
Linda received her Bachelor of Arts degree magna cum laude from Brooklyn College, her J.D. degree (with honors) from the National Law Center, George Washington University Law School, and her LLM in Taxation from New York University Law School.